News

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

- Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of…

12 months ago

Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones

Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operationsBRISBANE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) --…

12 months ago

Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation of GLP-1 Agonists with Nasal Anti-CD3

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology…

12 months ago

Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization

Company also reports preliminary unaudited 2024 revenue of $701.0 millionPARSIPPANY, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc.…

12 months ago

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

-- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025; expected to support global regulatory filings for…

12 months ago

Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…

12 months ago

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing…

12 months ago

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

-- Preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) of approximately $42 million for the fourth quarter of…

12 months ago

Y-mAbs Provides Strategic Business Update and 2025 Priorities

Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential…

12 months ago